FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593284859> ?p ?o ?g. }

• W2593284859 endingPage "134" @default.
• W2593284859 startingPage "134" @default.
• W2593284859 abstract "Abstract Background: Combination of Pegylated-Interferon alpha (Peg-IFNa) 2a and imatinib (IM) has been reported to significantly induce higher rates of molecular responses (including undetectable BCR-ABL transcript) over IM alone, as frontline therapy for CP-CML patients (pts) in a randomized phase 3 trial (SPIRIT, Preudhomme et al, NEJM 2010). Second generation TKIs such as dasatinib (DASISION, Kantarjian et al, NEJM 2010) enhance the speed and depth of molecular response (MR) in comparison to IM. Phase II trial using nilotinib and PegIFNa2a has recently reported high rates of deep molecular response (MR4.5) within 24 months (Nicolini FE et al, Lancet Haematology 2015). Aims: To determine the efficacy and safety of the combination of dasatinib and Peg-IFNa2b in CP-CML frontline. (EUDRACT Number: 2012-003389-42, Dasa-PegIFN trial). Methods: Newly diagnosed Ph+ CP-CML pts less than 65-year-old started dasatinib 100 mg/day. At 3 months, they were assigned to receive Peg-IFNa2b associated to dasatinib when platelets (plt) > 100 X 109/L, Neutrophils (ANC) > 1.5 X 109/L) and lymphocytes < 4.0 X 109/L counts were achieved. Otherwise, dasatinib was continued alone in the study according to the current international ELN guidelines. The maximum duration of the combination dasatinib and Peg-IFNa2b is 21 months. The primary endpoint is the cumulative rate of Molecular Response 4.5log (MR4.5 defined as BCR-ABL1/ABL1IS≤0.0032%) at 12 months. Molecular analyses were centralized and expressed according to the international scale (IS). Secondary endpoints included efficacy (cytogenetic and molecular responses at several time-points) and safety endpoints. Preliminary results are reported here. Results: 81 pts were enrolled between October 2013 and July 2014. All pts will have completed the 12 months follow-up time-point in August 2015. 79/81pts were included in the analysis (1 pt died of a CML-related haemorrhage before receiving dasatinib, 1 screening failure (masked Ph)). Median age was 48 (20-65) years. 54% of pts were male. Sokal scores were low, intermediate and high in 51%, 32% and 17% of pts respectively. After the first 3 months of therapy (M3), sixty-one patients (77%) started Peg-IFNa2b at the dose of 30 microg/week in association with dasatinib. For these pts after M3, reported hematologic adverse events (AE) were neutropenia (G3/4 n=11; G1/2 n=17), thrombocytopenia (G3/4 n=0; G1/2 n=7), anemia (G3/4 n=0; G1/2 n=7). Extra-hematologic AE were essentially of low grade (overall, G3/4 n=3; G1/2 n=113). According to NCI CTCAE V4.0, most frequent AE were infections (16%), general symptoms (15%), skin lesions (10%), hepato-biliary abnormalities (7.7%), nervous system/headache (7.7%) musculoskeletal pain (7%), psychiatric (7%), GI (6%) disorders. Eight serious AE (SAE) were reported after Peg-IFNa2b initiation: G4 neutropenia n=2, dysthyroitidis n=1, dyspnea n=1, pleural effusion n=1, lymphoid hyperplasia n=1, hemorrhoids n=1, rectal fistula (SUSAR) n=1. Efficacy was analysed according to the intention-to-treat principle (ITT), and considering missing data as no response to avoid inflated results. Overall at M3, 85% of pts had a BCR-ABL1/ABL1 ratio ≤10%. For eligible patients who received combined therapy (n=61), rates of MMR were 16%, 51%, 70%, and 70% (pending n=5) at M3, M6, M9 and M12, including MR4.5 rates 10%, 20%, 30% at M6, M9 and M12 respectively. Eighteen pts (22.7%) were not eligible to receive Peg-IFNa2b. Reasons, according to protocol criteria, were ANC <1.5 X 109/L (n=10), plt <100.0 X 109/L (n=5), lymphocytes >4.0 X 109/L (n=1), absence of complete hematologic response (n=1), non compliance (n=1). Rates of MMR for these pts were 27% at M6, 50 % at M9 (missing n=2), pending data for n=6 at M12. Conclusion: Peg-IFNa2b combined to dasatinib therapy in first line CP-CML induces a high rate of deep molecular response (ie MR4.5) during the first year of therapy. Despite few pending data, results at 12 months are already in line with previous data combining Peg-IFNa and TKI, expecting a potential for an increased rate in therapy cessation attempt. Preliminary data of this phase II trial indicate a manageable toxicity profile for this combination, despite an increased rate of neutropenia. Updated analyses (ITT and per protocol) will be presented for all the pts with at least 12 months follow-up. Disclosures ROY: BMS: Other: CongressTravels/Accomodations, Research Funding, Speakers Bureau; Novartis: Other: Congress Travels/Accomodations, Research Funding, Speakers Bureau; Merck: Other: Peg-Interferon provided in the trial. Guerci-Bresler:Novartis: Speakers Bureau; BMS: Speakers Bureau; ARIAD: Speakers Bureau; PFIZER: Speakers Bureau. Giraudier:BMS: Speakers Bureau; Novartis: Other: Congress Travel/Accomodation, Speakers Bureau. Johnson-Ansah:Hybrigenics SA: Consultancy, Research Funding; Novartis: Consultancy, Speakers Bureau; BMS: Speakers Bureau. Amé:Novartis: Speakers Bureau; BMS: Speakers Bureau. Etienne:BMS: Consultancy, Honoraria, Speakers Bureau; ARIAD: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Congress Travel/Accomodations, Research Funding, Speakers Bureau. Nicolini:BMS: Other: Travel/Accommodations/Expenses; Novartis: Other: Travel, Accommodations, Expenses; ARIAD: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Consulting or Advisory Role, Speakers Bureau; Novartis: Honoraria, Other: Consulting & Advisory Role, Research Funding, Speakers Bureau. Rea:Novartis: Honoraria; BMS: Honoraria; Ariad: Honoraria; Pfizer: Honoraria. Cony-Makhoul:Novartis: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau. Ianotto:Novartis: Other: Congress Travel/ Accomodations. Legros:ARIAD: Speakers Bureau; Novartis: Research Funding, Speakers Bureau; BMS: Speakers Bureau. Coiteux:BMS: Speakers Bureau. Hermet:BMS: Speakers Bureau; Novartis: Speakers Bureau. Mahon:BMS: Speakers Bureau; Novartis: Speakers Bureau. Rousselot:ARIAD: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Novartis: Speakers Bureau." @default.
• W2593284859 created "2017-03-16" @default.
• W2593284859 creator A5004066423 @default.
• W2593284859 creator A5007454329 @default.
• W2593284859 creator A5011326274 @default.
• W2593284859 creator A5012805294 @default.
• W2593284859 creator A5016240673 @default.
• W2593284859 creator A5025160152 @default.
• W2593284859 creator A5029914686 @default.
• W2593284859 creator A5033387273 @default.
• W2593284859 creator A5036560737 @default.
• W2593284859 creator A5038965613 @default.
• W2593284859 creator A5041434329 @default.
• W2593284859 creator A5044166434 @default.
• W2593284859 creator A5048325273 @default.
• W2593284859 creator A5051984074 @default.
• W2593284859 creator A5052564121 @default.
• W2593284859 creator A5055797334 @default.
• W2593284859 creator A5057643400 @default.
• W2593284859 creator A5066308745 @default.
• W2593284859 creator A5068342352 @default.
• W2593284859 creator A5069020012 @default.
• W2593284859 creator A5070207000 @default.
• W2593284859 creator A5070726308 @default.
• W2593284859 creator A5073015935 @default.
• W2593284859 creator A5075844368 @default.
• W2593284859 creator A5077014294 @default.
• W2593284859 creator A5078220154 @default.
• W2593284859 creator A5079181777 @default.
• W2593284859 creator A5083553066 @default.
• W2593284859 creator A5090679391 @default.
• W2593284859 date "2015-12-03" @default.
• W2593284859 modified "2023-10-16" @default.
• W2593284859 title "Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)" @default.
• W2593284859 doi "https://doi.org/10.1182/blood.v126.23.134.134" @default.
• W2593284859 hasPublicationYear "2015" @default.
• W2593284859 type Work @default.
• W2593284859 sameAs 2593284859 @default.
• W2593284859 citedByCount "10" @default.
• W2593284859 countsByYear W25932848592016 @default.
• W2593284859 countsByYear W25932848592017 @default.
• W2593284859 countsByYear W25932848592019 @default.
• W2593284859 countsByYear W25932848592021 @default.
• W2593284859 countsByYear W25932848592022 @default.
• W2593284859 countsByYear W25932848592023 @default.
• W2593284859 crossrefType "journal-article" @default.
• W2593284859 hasAuthorship W2593284859A5004066423 @default.
• W2593284859 hasAuthorship W2593284859A5007454329 @default.
• W2593284859 hasAuthorship W2593284859A5011326274 @default.
• W2593284859 hasAuthorship W2593284859A5012805294 @default.
• W2593284859 hasAuthorship W2593284859A5016240673 @default.
• W2593284859 hasAuthorship W2593284859A5025160152 @default.
• W2593284859 hasAuthorship W2593284859A5029914686 @default.
• W2593284859 hasAuthorship W2593284859A5033387273 @default.
• W2593284859 hasAuthorship W2593284859A5036560737 @default.
• W2593284859 hasAuthorship W2593284859A5038965613 @default.
• W2593284859 hasAuthorship W2593284859A5041434329 @default.
• W2593284859 hasAuthorship W2593284859A5044166434 @default.
• W2593284859 hasAuthorship W2593284859A5048325273 @default.
• W2593284859 hasAuthorship W2593284859A5051984074 @default.
• W2593284859 hasAuthorship W2593284859A5052564121 @default.
• W2593284859 hasAuthorship W2593284859A5055797334 @default.
• W2593284859 hasAuthorship W2593284859A5057643400 @default.
• W2593284859 hasAuthorship W2593284859A5066308745 @default.
• W2593284859 hasAuthorship W2593284859A5068342352 @default.
• W2593284859 hasAuthorship W2593284859A5069020012 @default.
• W2593284859 hasAuthorship W2593284859A5070207000 @default.
• W2593284859 hasAuthorship W2593284859A5070726308 @default.
• W2593284859 hasAuthorship W2593284859A5073015935 @default.
• W2593284859 hasAuthorship W2593284859A5075844368 @default.
• W2593284859 hasAuthorship W2593284859A5077014294 @default.
• W2593284859 hasAuthorship W2593284859A5078220154 @default.
• W2593284859 hasAuthorship W2593284859A5079181777 @default.
• W2593284859 hasAuthorship W2593284859A5083553066 @default.
• W2593284859 hasAuthorship W2593284859A5090679391 @default.
• W2593284859 hasConcept C126322002 @default.
• W2593284859 hasConcept C143998085 @default.
• W2593284859 hasConcept C168563851 @default.
• W2593284859 hasConcept C203014093 @default.
• W2593284859 hasConcept C203092338 @default.
• W2593284859 hasConcept C2522874641 @default.
• W2593284859 hasConcept C2776461080 @default.
• W2593284859 hasConcept C2777413986 @default.
• W2593284859 hasConcept C2777583451 @default.
• W2593284859 hasConcept C2778729363 @default.
• W2593284859 hasConcept C2779536868 @default.
• W2593284859 hasConcept C2780040827 @default.
• W2593284859 hasConcept C3019892230 @default.
• W2593284859 hasConcept C3020491458 @default.
• W2593284859 hasConcept C31760486 @default.
• W2593284859 hasConcept C535046627 @default.
• W2593284859 hasConcept C71924100 @default.
• W2593284859 hasConcept C90924648 @default.
• W2593284859 hasConceptScore W2593284859C126322002 @default.
• W2593284859 hasConceptScore W2593284859C143998085 @default.
• W2593284859 hasConceptScore W2593284859C168563851 @default.
• W2593284859 hasConceptScore W2593284859C203014093 @default.
• W2593284859 hasConceptScore W2593284859C203092338 @default.

• next